Impact of gestational SARS-CoV-2 and maternal inflammation on child growth and neurodevelopment in a malaria-endemic setting
疟疾流行环境中妊娠期 SARS-CoV-2 和母体炎症对儿童生长和神经发育的影响
基本信息
- 批准号:10722878
- 负责人:
- 金额:$ 19.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2028-08-31
- 项目状态:未结题
- 来源:
- 关键词:2 year old2019-nCoV4 year oldAddressAdverse effectsAfrica South of the SaharaAfricanAgeAntimalarialsBirthCOVID-19 pandemicCaringChemopreventionChildChildhoodClinicalClinical DataClinical ManagementClinical TrialsCohort StudiesCollaborationsCommunicable DiseasesComplexDataData SetDevelopmentDiagnosticDiscipline of obstetricsEnrollmentEpidemiologyExclusionExposure toFundingFutureGoalsGrowthImmuneImmune responseImmunityImmunologyImpairmentIncidenceInfantInfectionInflammationInflammation MediatorsInflammatoryInterleukin-1InterventionKnowledgeLong-Term EffectsLow Birth Weight InfantMalariaMediatingMentorshipMothersNeurocognitiveNeurocognitive DeficitNeuropsychologyOutcomePathway interactionsPediatricsPerinatal InfectionPlacebosPlasmaPopulationPregnancyPregnant WomenPremature BirthPrevention trialProteomicsPyrimethamineRandomizedRegimenResearchResearch PersonnelResource-limited settingResourcesRiskSARS-CoV-2 exposureSARS-CoV-2 immunitySARS-CoV-2 infectionSARS-CoV-2 variantSamplingSerology testSignal PathwaySulfadoxineTestingToddlerTrainingTranslational ResearchUgandaUnderweightUnited States National Institutes of HealthVaccinesWomancareer developmentclinically significantco-infectioncohortcytokineearly childhoodexperiencefightinggeographic populationglobal healthimprovedinfant outcomeinflammatory markerneurocognitive testneurodevelopmentoffspringpathogenseropositivetherapeutic targettranslational scientistvigilancewasting
项目摘要
PROJECT SUMMARY / ABSTRACT
Since the emergence of SARS-CoV-2 in 2020, millions of pregnancies in malaria-endemic sub-Saharan Africa
have been impacted by SARS-CoV-2 infection. High rates of SARS-CoV-2 and malaria co-infections during
pregnancy will continue as new SARS-CoV-2 variants emerge and cause re-infections in subsequent waves.
SARS-CoV-2 and malaria in pregnancy are both associated with adverse birth and infant outcomes – including
preterm birth, low birth weight, and impaired growth and neurodevelopment – possibly mediated through
maternal inflammation. Data on long-term developmental effects of gestational SARS-CoV-2 in highly malaria
exposed populations are lacking. To address this gap, I will leverage samples and data from mother-infant dyads
enrolled in two complementary ongoing NIH-funded antimalarial chemoprevention trials in Busia, Uganda. In the
pregnancy trial, pregnant women are randomized to one of three antimalarial chemoprevention regimens and
followed through delivery; infants born to these women are being randomized in a separate clinical trial to receive
antimalarial chemoprevention or placebo and followed to age 4 years. These trials have coincided with Uganda’s
early SARS-CoV-2 surges, and preliminary data indicate high incidence of both SARS-CoV-2 and malaria during
pregnancy. Using clinical data and samples collected as part of the ongoing trials, I will test the hypothesis that
infants exposed to gestational SARS-CoV-2 will have impaired growth and neurodevelopment in early childhood
when compared with unexposed infants, and that this is mediated by maternal inflammation. I further hypothesize
that exposure to both SARS-CoV-2 and malaria in pregnancy increases adverse infant outcomes due to the
synergistic inflammatory effects of both pathogens. In Aim 1, I will use serologic testing of stored plasma samples
to retrospectively identify mothers who experienced SARS-CoV-2 during pregnancy and compare the growth of
infants with and without gestational SARS-CoV-2 exposure through age 4 years. In Aim 2, I will compare
neurocognitive test scores at ages 24 and 42 months among infants with and without gestational SARS-CoV-2.
In Aim 3, I will explore maternal proteomic immune signatures of SARS-CoV-2 in pregnancy and determine if
the effect of gestational SARS-CoV-2 on infant growth and neurodevelopment is mediated by specific
inflammatory pathways. This cohort is uniquely poised to address the impact of SARS-CoV-2 in pregnancy in a
malaria endemic setting, with longitudinal data and samples collected before widespread baseline SARS-CoV-
2 immunity. To accomplish these aims and become an independent translational researcher in tropical perinatal
infections, I have assembled an interdisciplinary mentorship team of experts in in infectious diseases, obstetrics,
pediatrics, neuropsychology, immunology, and global health. Results from this proposed study have immediate
implications for improving care of at-risk infants, and could identify diagnostic or therapeutic targets for future
clinical interventions.
项目摘要/摘要
自2020年出现SARS-CoV-2以来,在疟疾流行的撒哈拉以南非洲地区,数百万名孕妇
都受到了SARS-CoV-2感染的影响。年SARS-CoV-2和疟疾混合感染率较高
随着新的SARS-CoV-2变种的出现,怀孕将继续,并在随后的几波中导致再次感染。
SARS-CoV-2和孕期疟疾都与不良分娩和婴儿结局有关--包括
早产、低出生体重以及生长和神经发育受损--可能是通过
母体炎症。高度疟疾患者孕期SARS-CoV-2的长期发育影响资料
受感染的人群很少。为了解决这一差距,我将利用母婴二人组的样本和数据
在乌干达布西亚参加了由美国国立卫生研究院资助的两项互补的正在进行的抗疟疾化学预防试验。在
怀孕试验中,孕妇被随机分成三种抗疟疾化学预防方案之一和
通过分娩进行跟踪;这些妇女所生的婴儿在一项单独的临床试验中被随机接受
抗疟疾化学预防或安慰剂,并跟踪至4岁。这些审判与乌干达的
早期SARS-CoV-2激增,初步数据显示SARS-CoV-2和疟疾在
怀孕了。使用作为正在进行的试验的一部分收集的临床数据和样本,我将检验以下假设
孕期感染SARS-CoV-2的婴儿在儿童早期会有生长和神经发育障碍
与未暴露的婴儿相比,这是由母体炎症介导的。我进一步假设
怀孕期间接触SARS-CoV-2和疟疾会增加婴儿的不良结局,这是因为
两种病原体的协同炎症作用。在目标1中,我将使用存储的血浆样本的血清学测试
对孕期感染SARS-CoV-2的母亲进行回顾性鉴定,比较孕期母亲的生长发育情况
有和没有孕期接触SARS-CoV-2的婴儿一直持续到4岁。在《目标2》中,我将比较
患有和没有感染SARS-CoV-2的婴儿在24和42个月时的神经认知测试得分。
在目标3中,我将探索怀孕期间SARS-CoV-2的母体蛋白质组免疫特征,并确定
妊娠SARS-CoV-2对婴儿生长和神经发育的影响是通过特异性介导的
炎症途径。这一队列独特地准备好应对SARS-CoV-2在怀孕期间对
疟疾流行环境,在流行基线SARS-CoV之前收集的纵向数据和样本-
2豁免权。实现这些目标,成为热带围产期的独立翻译研究人员
传染病,我组建了一个跨学科的专家导师团队,在传染病,产科,
儿科学、神经心理学、免疫学和全球卫生。这项拟议的研究的结果立即
对改善高危婴儿护理的影响,并可以确定未来的诊断或治疗目标
临床干预。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Karen Blake Jacobson其他文献
Karen Blake Jacobson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
微米和纳米塑料作用下2019-nCoV抗病毒药物利巴韦林对河蚬的毒性作用机制
- 批准号:
- 批准年份:2021
- 资助金额:10.0 万元
- 项目类别:省市级项目
2019-nCoV感染导致人体淋巴细胞减低机制及其对机体免疫功能影响
- 批准号:82030002
- 批准年份:2020
- 资助金额:135 万元
- 项目类别:专项基金项目
基于人口流动大数据的新型冠状病毒(2019-nCoV)输出感染风险及接触网络传播模型研究
- 批准号:
- 批准年份:2020
- 资助金额:135 万元
- 项目类别:
新型冠状病毒(2019-nCoV)反向遗传系统及啮齿类感染模型的建立与应用
- 批准号:
- 批准年份:2020
- 资助金额:150 万元
- 项目类别:
血必净预防2019-nCoV肺炎发生ARDS及机制研究
- 批准号:82041003
- 批准年份:2020
- 资助金额:135 万元
- 项目类别:专项基金项目
云南驯养野生动物中新型冠状病毒(2019-nCoV)溯源调查与验证
- 批准号:
- 批准年份:2020
- 资助金额:140 万元
- 项目类别:
新型冠状病毒2019-nCoV复制复合体关键蛋白的功能与潜在药物靶点研究
- 批准号:
- 批准年份:2020
- 资助金额:150 万元
- 项目类别:专项基金项目
2019-nCoV蝙蝠及人群代表性流行株致病能力的比较研究
- 批准号:
- 批准年份:2020
- 资助金额:150 万元
- 项目类别:专项基金项目
人新型冠状病毒2019-nCoV受体利用介导的种间传播和感染机制研究
- 批准号:
- 批准年份:2020
- 资助金额:140 万元
- 项目类别:专项基金项目
新型冠状病毒2019-nCoV重要复制加帽酶的工作机制研究
- 批准号:
- 批准年份:2020
- 资助金额:150 万元
- 项目类别:专项基金项目
相似海外基金
COVID-19 Variant Supplement - Targeting programmed ribosomal frameshifting as a therapeutic strategy against 2019-nCoV
COVID-19 变异补充剂 - 以程序化核糖体移码为目标作为针对 2019-nCoV 的治疗策略
- 批准号:
443173 - 财政年份:2021
- 资助金额:
$ 19.33万 - 项目类别:
Operating Grants
Destigmatizing Chinese Communities in the face of 2019-nCoV: Emergency Management Actions to Address Social Vulnerability in Toronto and Nairobi
面对 2019-nCoV,消除华人社区的污名化:解决多伦多和内罗毕社会脆弱性的应急管理行动
- 批准号:
422610 - 财政年份:2020
- 资助金额:
$ 19.33万 - 项目类别:
Operating Grants
Task A38: Establishment of Small Animal Models for Screening Medical Countermeasures for the 2019 Novel Coronavirus (2019-nCoV)
任务A38:建立用于筛选2019新型冠状病毒(2019-nCoV)医疗对策的小动物模型
- 批准号:
10330359 - 财政年份:2020
- 资助金额:
$ 19.33万 - 项目类别:
Task A38: Establishment of Small Animal Models for Screening Medical Countermeasures for the 2019 Novel Coronavirus (2019-nCoV)
任务A38:建立用于筛选2019新型冠状病毒(2019-nCoV)医疗对策的小动物模型
- 批准号:
10454575 - 财政年份:2020
- 资助金额:
$ 19.33万 - 项目类别:
Task A38: Establishment of Small Animal Models for Screening Medical Countermeasures for the 2019 Novel Coronavirus (2019-nCoV)
任务A38:建立用于筛选2019新型冠状病毒(2019-nCoV)医疗对策的小动物模型
- 批准号:
10454574 - 财政年份:2020
- 资助金额:
$ 19.33万 - 项目类别:
Task A38: Establishment of Small Animal Models for Screening Medical Countermeasures for the 2019 Novel Coronavirus (2019-nCoV)
任务A38:建立用于筛选2019新型冠状病毒(2019-nCoV)医疗对策的小动物模型
- 批准号:
10579807 - 财政年份:2020
- 资助金额:
$ 19.33万 - 项目类别:
Targeting programmed ribosomal frameshifting as a therapeutic strategy against 2019-nCoV
以程序化核糖体移码为目标作为针对 2019-nCoV 的治疗策略
- 批准号:
422724 - 财政年份:2020
- 资助金额:
$ 19.33万 - 项目类别:
Operating Grants
RAPID Proposal: Psychological distance and risk perception related to the 2019 novel coronavirus (2019-nCoV) outbreak
RAPID提案:与2019年新型冠状病毒(2019-nCoV)爆发相关的心理距离和风险感知
- 批准号:
2020597 - 财政年份:2020
- 资助金额:
$ 19.33万 - 项目类别:
Standard Grant
Task A38: Establishment of Small Animal Models for Screening MCMs for the 2019 Novel Coronavirus (2019-nCoV)
任务 A38:建立用于筛选 2019 年新型冠状病毒(2019-nCoV)的 MCM 的小动物模型
- 批准号:
10473626 - 财政年份:2020
- 资助金额:
$ 19.33万 - 项目类别:
Task A38: Establishment of Small Animal Models for Screening Medical Countermeasures for the 2019 Novel Coronavirus (2019-nCoV)
任务A38:建立用于筛选2019新型冠状病毒(2019-nCoV)医疗对策的小动物模型
- 批准号:
10464972 - 财政年份:2020
- 资助金额:
$ 19.33万 - 项目类别:














{{item.name}}会员




